Click it and Unblock the Notifications
Latest Updates
-
Why Indians Are Depending Too Heavily on Supplements — And What Doctors Want You to Know -
Throwback Thursday: When Sanjeev Kumar Played Elderly Roles Before 30 And 9 Characters In One Movie -
Amitabh Bachchan's Misunderstood Blog Sparked Concern, But His Real Medical Battles Define Resilience -
Jaipur Ranks 6th Among World's Happiest Cities 2026: The Culture Behind The Joy -
Why Green Is the Colour of Sawan: History, Symbolism, and Styling Tips -
Legionnaires' Disease Outbreak: What It Is, Symptoms, Causes, And Prevention Explained -
Ananya Panday's Gaurav Gupta Couture Featured 12,000 Pearls, 2,600 Petals And A Celestial Love Story -
Kharchi Puja 2026: Tripura's Ancient Festival Where The Heads Of Fourteen Deities Are Worshipped -
World Brain Day 2026: How Quality Sleep Helps Safeguard Your Brain Health -
National Mango Day 2026: Why Mango Is Called The 'King Of Fruits' And What Sets It Apart
Personalized Blood Tests For Cancer Patients
Boffins have used data from the whole genome sequencing of cancer patients to develop individualized blood tests which he believes can help physicians tailor patients' treatments.
"We believe this is the first application of newer generations of whole-genome sequencing that could be clinically useful for cancer patients.Using this approach, we can develop biomarkers for potentially any cancer patient." says Victor Velculescu, M.D., Ph.D., associate professor of oncology and co-director of the cancer biology Johns Hopkins."
In a report on the work, published in the February 24 issue of Science Translational Medicine, show that unlike any other kind researches they are studying the rearrangements of large chunks of DNA rather than changes in a single DNA letter among billions of others. They term it their new approach Personalized Analysis of Rearranged Ends (PARE).
Such DNA rearrangements are widely known to occur exclusively in cancer cells, not normal ones, making them ideal biomarkers for cancer.
Using six sets of cancerous and normal tissue samples taken from four colorectal and two breast cancer patients, the Johns Hopkins team used next-generation DNA sequencing methods to catalogue the genome sequence data of each patient.
After investigators identified DNA rearrangements in patients' tumor samples, they looked for similar changes in DNA shed from tumors into the patients' blood.
Taking and matching these samples, they amplified DNA found in the blood and determined that these tests were sensitive enough to detect rearranged tumor DNA in these samples.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.
Continue with Google